NCT03702894View on ClinicalTrials.gov

Bioequivalence Study of Clavamox, Film-coated Tablets, 875 mg + 125 mg Pharmtechnology LLC, Belarus), and Augmentin®, Film-coated Tablets, 875 mg + 125 mg (GlaxoSmithKline Trading CJSC, Russia), in Healthy Volunteers Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

September 21, 2018

Primary Completion Date

October 8, 2018

Study Completion Date

October 8, 2018

Conditions
Bioequivalence
Interventions
DRUG

Clavamox

Clavamox, Film-coated Tablets, 875 mg + 125 mg, manufactured by Pharmtechnology LLC, Belarus

DRUG

Augmentin®

Augmentin®, Film-coated Tablets, 875 mg + 125 mg, marketed by GlaxoSmithKline Trading CJSC, Russia

Trial Locations (1)

150010

"State Autonomous Healthcare Facility of the Yaroslavl Region Clinical Hospital No. 2", Yaroslavl

All Listed Sponsors
collaborator

ClinPharmInvest, LLC

OTHER

lead

Pharmtechnology LLC

INDUSTRY

NCT03702894 - Bioequivalence Study of Clavamox, Film-coated Tablets, 875 mg + 125 mg Pharmtechnology LLC, Belarus), and Augmentin®, Film-coated Tablets, 875 mg + 125 mg (GlaxoSmithKline Trading CJSC, Russia), in Healthy Volunteers Under Fasting Conditions | Biotech Hunter | Biotech Hunter